Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B

Human Gene Therapy

Volumn 20, Issue 5, 2009, Pages 479-485

  Brunetti Pierri, Nicola ^a   Grove, Nathan C ^a   Zuo, Yu ^a   Edwards, Rachel ^b   Palmer, Donna ^a   Cerullo, Vincenzo ^a   Teruya, Jun ^b   Ng, Philip ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENETIC ENGINEERING; HEMOPHILIA B; MOUSE; NONHUMAN; PROTEIN DOMAIN; THROMBOGENICITY; TOXICITY TESTING; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

ANIMALS; FACTOR IX; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; THROMBOSIS; TRANSDUCTION, GENETIC;

MUS;

EID: 66149107357     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.084     Document Type: Article

References (18)

1. Beale, E.G., Clouthier, D.E., and Hammer, R.E. (1992). Cell-specific expression of cytosolic phosphoenolpyruvate carboxykinase in transgenic mice. FASEB J. 6, 3330-3337.
2. Brunetti-Pierri, N., Palmer, D.J., Beaudet, A.L., Carey, K.D., Finegold, M., and Ng, P. (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15, 35-46.
3. Brunetti-Pierri, N., Nichols, T.C., McCorquodale, S., Merricks, E., Palmer, D.J., Beaudet, A.L., and Ng, P. (2005a). Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum. Gene Ther. 16, 811-820.
4. Brunetti-Pierri, N., Palmer, D.J., Mane, V., Finegold, M., Beaudet, A.L., and Ng, P. (2005b). Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol. Ther. 12, 99-106.
5. Chang, J., Jin, J., Lollar, P., Bode, W., Brandstetter, H., Hamaguchi, N., Straight, D.L., and Stafford, D.W. (1998). Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J. Biol. Chem. 273, 12089-12094.
6. Chang, J.Y., Monroe, D.M., Stafford, D.W., Brinkhous, K.M., and Roberts, H.R. (1997). Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J. Clin. Invest. 100, 886-892.
7. Ehrhardt, A., and Kay, M.A. (2002). A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99, 3923-3930.
8. Lofqvist, T., Nilsson, I.M., Berntorp, E., and Pettersson, H. (1997). Haemophilia prophylaxis in young patients: A longterm follow-up. J. Intern. Med. 241, 395-400.
9. Manco-Johnson, M.J., Nuss, R., Geraghty, S., Funk, S., and Kilcoyne, R. (1994). Results of secondary prophylaxis in children with severe hemophilia. Am. J. Hematol. 47, 113-117.
10. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P.K., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A., and Kay, M.A. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
11. Mingozzi, F., and High, K.A. (2007). Immune responses to AAV in clinical trials. Curr. Gene Ther. 7, 316-324.
12. + T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422.
13. Morral, N., O'Neal, W.K., Rice, K., Leland, M.M., Piedra, P.A., Aguilar-Cordova, E., Carey, K.D., Beaudet, A.L., and Langston, C. (2002). Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther. 13, 143-154.
14. Palmer, D.J., and Ng, P. (2003). Improved system for helper-dependent adenoviral vector production. Mol. Ther. 8, 846-852.
15. Palmer, D.J., and Ng, P. (2004). Physical and infectious titers of helper-dependent adenoviral vectors: A method of direct comparison to the adenovirus reference material. Mol. Ther. 10, 792-798.
16. Ragni, M.V. (2004). Hemophilia gene transfer: comparison with conventional protein replacement therapy. Semin. Thromb. Hemost. 30, 239-247.
17. Schuettrumpf, J., Herzog, R.W., Schlachterman, A., Kaufhold, A., Stafford, D.W., and Arruda, V.R. (2005). Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 105, 2316-2323.
18. Wang, L., Zoppe, M., Hackeng, T.M., Griffin, J.H., Lee, K.F., and Verma, I.M. (1997). A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 11563-11566.